Positive and negative effects of thalidomide on refractory cutaneous lupus erythematosus

Autoimmunity

Volumn 38, Issue 7, 2005, Pages 549-555

  Briani, Chiara ^a   Zara, G ^a   Rondinone, R ^a   Iaccarino, L ^a   Ruggero, S ^a   Toffanin, E ^a   Ermani, M ^a   Ghirardello, A ^a   Zampieri, S ^a   Sarzi Puttini, P ^b   Doria, A ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Lupus erythematosus; Neurotoxicity; Peripheral neuropathy; Thalidomide

Indexed keywords

ANTICOAGULANT AGENT; CHLOROQUINE; GABAPENTIN; STEROID; THALIDOMIDE;

ADULT; AGE; AMENORRHEA; ARTERY THROMBOSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; LOW DRUG DOSE; NERVE POTENTIAL; PARESTHESIA; PERIPHERAL NEUROPATHY; PROSPECTIVE STUDY; RANK SUM TEST; SENSORY NEUROPATHY; SKIN LUPUS ERYTHEMATOSUS; SKIN MANIFESTATION; SOMNOLENCE; THERAPY RESISTANCE; THORAX PAIN; TREATMENT FAILURE; TREMOR;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGY; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, CUTANEOUS; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM DISEASES; THALIDOMIDE;

EID: 30844443931     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.1080/08916930500285790     Document Type: Article

References (34)

1. Karim, MY and Ruiz-Irastorza, G and Khamashta, MA and Hughes, GR. (2001) Update on therapy-thalidomide in the treatment of lupus Lupus, 10, pp. 188-192.
2. Tseng, S and Pak, G and Washenik, K and Pomeranz, MK and Shupack, JL. (1996) Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses J Am Acad Dermatol, 35, pp. 969-979.
3. Zampieri S, Alaibac M, Iaccarino L, Rondinone R, Ghirardello A, Sarzi-Puttini P, Peserico A, Doria A. TNF-α is expressed in refractory skin lesions from subacute cutaneous lupus erythematosus patients. Ann Rheum Dis 2005; in press.
4. Sheskin, J. (1980) The treatment of lepra reaction in lepromatosus leprosy. Fifteen years' experience with thalidomide Int J Dermatol, 19, pp. 318-322.
5. Wulff, CH and Hoyer, H and Asboc-Hansen, G and Brodthagen, H. (1985) Development of polyneuropathy during thalidomide therapy Br J Dermatol, 112, pp. 475-480.
6. Knop, J and Bonsmann, G and Happle, R and (1983) Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus Br J Dermatol, 108, pp. 461-466.
7. Bastuji-Garin, S and Ochonisky, S and Bouche, P and (2002) Incidence and risk factors for thalidomide neuropathy: A prospective study of 135 dermatologic patients J Investig Dermatol, 119, pp. 1020-1026.
8. Fullerton, PM and O'Sullivan, J. (1968) Thalidomide neuropathy; a clinical, electrophysiological, and histological follow-up study J Neurol Neurosurg Psychiat, 31, pp. 543-551.
9. Calabrese, L and Fleischer, AB, Jr. (2000) Thalidomide: Current and potential clinical applications Am J Med, 108, pp. 487-495.
10. Chaudhry, V and Cornblath, DR and Corse, A and (2002) Thalidomide-induced neuropathy Neurology, 59, pp. 1872-1875.
11. Gardner-Medwin, JMM and Smith, NJ and Powell, RJ. (1994) Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet's disease: Use of neurophysiological studies to detect thalidomide neuropathy Ann Rheum Dis, 53, pp. 828-832.
12. Ochonisky, S and Verroust, J and Bastuji-Garin, S and Gherardi, R and Revuz, J. (1994) Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients Arch Dermatol, 130, pp. 66-69.
13. Chaudhry, V and Chaudhry, M and Crawford, TO and Simmons-O'Brien, E and Griffin, JW. (2003) Toxic neuropathy in patients with pre-existing neuropathy Neurology, 60, pp. 337-340.
14. Tan, EM and Cohen, AS and Fries, JF and (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus Arthritis Rheum, 25, pp. 1271-1277.
15. American Rheumatism Association Glossary Committee.(1982) Dictionary of the rheumatic disease: Signs and symptoms. Bayport, New York: Conctact Associates International. 1st edn.
16. Harris, EN. (1990) Antiphospholipid antibodies Br J Haematol, 74, pp. 1-9.
17. Vitali, C and Bencivelli, W and Isenberg, DA and (1992) Disease activity in systemic lupus erythematosus: Report of the Consensus Study Group of the European Workshop for Rheumatology Research. II Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE Clin Exp Rheumatol, 10, pp. 541-547.
18. Gladman, D and Ginzler, E and Goldsmith, C and (1996) The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus Arthritis Rheum, 39, pp. 363-369.
19. Dyck, PJ. (1988) Detection, characterization, and staging of polyneuropathy: Assessed in diabetics Muscle Nerve, 11, pp. 21-32.
20. Notermans, NC and Wokke, JH and Lokhorst, HM and Franssen, H and van der Graaf, Y and Jennekens, FG. (1994) Polyneuropathy associated with monoclonal gammopathy of undetermined significance. A prospective study of the prognostic value of clinical and laboratory abnormalities Brain, 117, pp. 1385-1393.
21. van Swieten, JC and Koudstaal, PJ and Visser, MC and Schouten, HJ and van Gijn, J. (1988) Interobserver agreement for the assessment of handicap in stroke patients Stroke, 19, pp. 604-607.
22. Rinaldi, S and Doria, A and Salaffi, F and Ermani, M and Iaccarino, L and Ghirardello, A and Zampieri, S and Gambari, PF and Perini, G. (2004) Health-related quality of life in Italian patients with systemic lupus erythematosus. I. Relationship between physical and mental dimension and impact of age Rheumatology, 43, pp. 1574-1579.
23. Doria, A and Rinaldi, S and Ermani, M and Salaffi, F and Iaccarino, L and Ghirardello, A and Zampieri, S and Della Libera, S and Perini, G and Todesco, S. (2004) Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological, and psychological determinants Rheumatology, 43, pp. 1580-1586.
24. Housman, TS and Jorizzo, JL and McCarty, MA and Grummer, SE and Fleischer, AB, Jr and Sutej, PG. (2003) Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus Arch Dermatol, 139, pp. 50-54.
25. Lagueny, A and Rommel, A and Vignolly, B and (1986) Thalidomide neuropathy: An electrophysiologic study Muscle Nerve, 9, pp. 837-844.
26. Clemmensen, OJ and Olsen, PZ and Andersen, KE. (1984) Thalidomide neurotoxicity Arch Dermatol, 120, pp. 338-341.
27. Giannini, F and Volpi, N and Rossi, S and Passero, S and Fimiani, M and Cerase, A. (2003) Thalidomide-induced neuropathy: A ganglionopathy? Neurology, 60, pp. 877-878.
28. Hess, CW and Hunziker, T and Kupfer, A and Ludin, HP. (1986) Thalidomide-induced peripheral neuropathy. A prospective clinical, neurophysiological and pharmacogenetic evaluation J Neurol, 233, pp. 83-89.
29. Harland, CC and Steventon, GB and Marsden, JR. (1995) Thalidomide-induced neuropathy and genetic differences in drug metabolism Eur J Clin Pharmacol, 49, pp. 1-6.
30. Hamanoue, M and Middleton, G and Wyatt, S and Jaffray, E and Hay, RT and Davies, AM. (1999) p75-mediated NF-kappaB activation enhances the survival response of developing sensory neurons to nerve growth factor Mol Cell Neurosci, 14, pp. 28-40.
31. Flageul, B and Wallach, D and Cavelier-Balloy, B and Bachelez, H and Carsuzaa, F and Dubertret, L. (2000) Thalidomide and Thrombosis Ann Dermatol Venereol, 127, pp. 171-174.
32. Ghirardello, A and Doria, A and Ruffatti, A and (1994) Antiphospholipid antibodies (aPL) in systemic lupus erythematosus (SLE). Are they specific tools for the diagnosis of aPL syndrome in SLE? Ann Rheum Dis, 53, pp. 40-42.
33. Doria, A and Ghirardello, A and Boscaro, M and (1995) Fibrinolysis and coagulation abnormalities in systemic lupus erythematosus. Relationship with Raynaud's phenomenon, disease activity, inflammatory indices, anticardiolipin antibodies and corticosteroid therapy Rheumatol Int, 14, pp. 207-211.
34. Piette, J-C and Sbaï, A and Francès, C. (2002) Warning: Thalidomide-related thrombotic risk potentially concerns patients with lupus Lupus, 11, pp. 67-70.